オプションチェーンは、LeddarTech Holdingsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、LeddarTech Holdingsの市場センチメントを評価します。.

LeddarTech Holdings (NASDAQ:LDTC) 株価情報, オプションチェーン

LeddarTech Holdings

LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.

LeddarTech Holdings Inc

Oppenheimer analyst Tyler Batory maintains Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) with a Outperform and maintains $189 price target.

News

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Toll Brothers, Maintains $189 Price Target

SEER commits to an aggressive decarbonization and carbon credit monetization program, starting with its current MV Technology solutions and its planned biocarbon production facilities both domestic and international.
BROOMFIELD, CO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=wWeNjwuKVscfBb8iSWOS6KOuFfYlgP58VnQyWCNR511nEpHCQXzFlBti48KxNYSVU_evWbbJWyjcNCbVKaWi76UC1ezMdpTe9bAzxBsyaEk38VpWN34Vpu2tD40OrWRZECsBkx6x6YMuAHU6Rih8Ng==">Strategic Environmental &amp; Energy Resources, Inc.</a>&nbsp;(SEER) (OTCQB:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=otIrNvpDfGrtGkckwPgtulP1h5Fz0sWWOuac9wpq5raSQzkxrQQalVKqTw-qetqs86YhbAiBrzg0dDyVvjXZtRZB_yPQWnuiK9r6Bo_EyDY=">SENR</a>), a provider of environmental, renewable fuels and industrial waste stream management services, has partnered with DevvStream, Inc., an emerging leader in carbon credit investing and monetization (<a href="https://www.globenewswire.com/Tracker?data=1UAN8Rn2W5rFehi5-1tNUr1BQhVfp5JR27cqT9D7bburUsOAG-Ter-HdbRJastHpys4HEBbNSCJyeA5ocxZjOx7jK8LpYWcSVM2UOL77MrQ=">https://www.devvstream.com/</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>). Together, SEER and DevvStream, intend to develop a comprehensive program to quantify and monetize high-quality carbon credits arising out of 1) biogas capture and conditioning associated with generating methane renewable energy, 2) the prevention of harmful fugitive emissions from small, vertical oil &amp; gas wells, and 3) the sequestration of CO2 at SEER's planned "biocarbon" production facilities in Texas and Saudi Arabia.

Global

DEVS

Seer Partners With Devvstream To Monetize Insured Carbon Credits Arising Out Of Biogas Capture And Conditioning Associated With Generating Methane Renewable Energy, The Prevention Of Harmful Fugitive Emissions From Small, Vertical Oil & Gas Wells, And The Sequestration Of CO2 At SEER's Planned "Biocarbon" Production Facilities In Texas And Saudi Arabia

Trading Ideas

APVO

Aptevo Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 39%

Wells Fargo analyst Zachary Fadem upgrades Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) from Underweight to Equal-Weight and raises the price target from $95 to $130.

Upgrades

Wells Fargo Upgrades Brinker International to Equal-Weight, Raises Price Target to $130

Oppenheimer analyst Chris Kotowski maintains StepStone Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEP#NASDAQ">STEP</a>) with a Outperform and raises the price target from $73 to $84.

STEP

Oppenheimer Maintains Outperform on StepStone Group, Raises Price Target to $84

Journal is the official publication of the International Union of Immunological Societies
Marlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL&#xAE; siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells announced today its manuscript, Self-delivering RNAi Immunotherapeutic PH-762 Silences PD-1 to Generate Local and Abscopal Anti-tumor Efficacy, has been published in the December, 2024 issue of Frontiers in Immunology.
The article presents preclinical proof-of-concept data for PH-762, an INTASYL compound designed to silence PD-1, is currently in clinical development for advanced cutaneous malignancies. Phio recently presented data from its second cohort in its on-going Phase 1b clinical trial showing one patient with cutaneous squamous cell carcinoma in the 2nd cohort achieved a complete response (100% tumor clearance) while a second patient with squamous cell carcinoma achieved a partial response (90% tumor clearance).

Biotech

General

PHIO

Phio Pharmaceuticals Announces Publication In Frontiers In Immunology Announces Its Manuscript, Self-Delivering RNAi Immunotherapeutic PH-762 Silences PD-1 To Generate Local And Abscopal Anti-Tumor Efficacy, Has Been Published In The December, 2024 Issue Of Frontiers In Immunology

Oppenheimer analyst Chris Kotowski maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Outperform and raises the price target from $17 to $21.

Oppenheimer Maintains Outperform on P10, Raises Price Target to $21

Oppenheimer analyst Chris Kotowski maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Outperform and raises the price target from $153 to $175.

Oppenheimer Maintains Outperform on KKR, Raises Price Target to $175

MULN

Mullen Subsidiary, Bollinger Motors, Delivered First 25 B4 Trucks, With Retail Sales Of ~$4.1M Nearly Three Months Since Start Of Production In Sept.

Oppenheimer analyst Chris Kotowski maintains GCM Grosvenor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) with a Outperform and raises the price target from $18 to $20.

GCMG

Oppenheimer Maintains Outperform on GCM Grosvenor, Raises Price Target to $20

Leerink Partners analyst Daina Graybosch downgrades LAVA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) from Outperform to Market Perform and lowers the price target from $11 to $2.

Downgrades

LVTX

Leerink Partners Downgrades LAVA Therapeutics to Market Perform, Lowers Price Target to $2

Terreno Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, acquired an industrial property located in Red Hook, Brooklyn, New York, on December 11, 2024 for a purchase price of approximately $156.3 million. The purchase price includes the assumption of an approximately $72.9 million 3.85% interest-only loan which matures in March 2028.
The property consists of one 36-foot clear height industrial distribution building containing approximately 312,000 leasable square feet on 16.0 acres. The property is at 280 Richards Street, provides five dock-high and five grade-level loading positions and parking for 349 cars, including 179 rooftop parking positions. The property has riparian access, is 100% leased to a leading e-commerce firm and the estimated stabilized cap rate is 4.8%.

TRNO

Terreno Realty Corporation Acquires Property In Brooklyn, NY, For $156.3M

ExlService Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>) has outperformed the market over the past 10 years by 12.17% on an annualized basis producing an average annual return of 23.82%. Currently, ExlService Holdings has a market capitalization of $7.41 billion. 
Buying $1000 In EXLS: If an investor had bought $1000 of EXLS stock 10 years ago, it would be worth $8,802.12 today based on a price of $46.07 for EXLS at the time of writing.
<h3>ExlService Holdings's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734013823_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXLS

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Zeta Global Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) short percent of float has risen 17.89% since its last report. The company recently reported that it has 15.54 million shares sold short, which is 8.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zeta Global Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734013821_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zeta Global Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Zeta Global Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zeta Global Holdings's peer group average for short interest as a percentage of float is 8.90%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

ZETA

How Is The Market Feeling About Zeta Global Holdings?

Tonix Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NYSE">TNXP</a>) short percent of float has fallen 69.53% since its last report. The company recently reported that it has 1.59 million shares sold short, which is 0.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tonix Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734013816_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 4.37%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TNXP

How Is The Market Feeling About Tonix Pharmaceuticals?

3M's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) short percent of float has fallen 4.88% since its last report. The company recently reported that it has 6.34 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>3M Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734013810_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for 3M has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing 3M's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, 3M's peer group average for short interest as a percentage of float is 3.84%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About 3M?

Oppenheimer analyst Chris Kotowski maintains Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Outperform and raises the price target from $24 to $28.

Oppenheimer Maintains Outperform on Blue Owl Cap, Raises Price Target to $28

Castor Maritime Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRM#NASDAQ">CTRM</a>), ("Castor" or the "Company"), a diversified global shipping company, announces that on December 12, 2024, it entered, through a wholly owned subsidiary, into an Share Purchase Agreement ("SPA") with MPC Münchmeyer Petersen &amp; Co. GmbH ("MPC Holding") for the acquisition of 26,116,378 shares representing 74.09% of the shares of the Frankfurt-listed investment and asset manager MPC Münchmeyer Petersen Capital AG (Deutsche Börse, Scale, ISIN DE000A1TNWJ4) ("MPC Capital").
The acquisition price of the shares has been agreed at a price of €7.00 per share, which is equal to an aggregate cost of €182.8 million payable in cash (approx. USD 192.6 million equivalent), excluding any transaction-related costs. As part of the transaction Castor secured a $100,000,000 new senior term loan facility and $50,000,000 proceeds from the issuance of 50,000 additional Series D cumulative convertible preferred shares, both from Toro Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TORO#NASDAQ">TORO</a>), ("Toro"), an entity controlled by Petros Panagiotidis, Castor's Chairman and CEO.

CTRM

TORO

Castor Maritime Enters Into An Share Purchase Agreement With MPC Münchmeyer Petersen & Co. GmbH For The Acquisition Of 26,116,378 Shares Representing 74.09% Of The Shares For ~$192.6M

On Thursday, Keros Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial Phase 2 trial of cibotercept (KER-012) in combination with background therapy in pulmonary <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42456129/keros-therapeutics-announces-update-on-the-phase-2-tropos-trial" rel="noreferrer noopener">arterial hypertension patients</a>.
The move is based on a safety review, as the trial unanticipatedly observed adverse pericardial effusion events.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42297870/keros-therapeutics-licensing-deal-with-takeda-aligns-with-broader-opportunity-for-elritercept-analyst" rel="noreferrer noopener">Keros Therapeutics&#8217; Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst</a>
Pericardial effusion is&nbsp;when too much fluid builds up in the sac around the heart, called the pericardium.&nbsp;This fluid can pressure the heart, making it difficult to function properly.
The TROPOS trial is fully enrolled, and dosing in the 1.5 mg/kg treatment arm remains ongoing following completion of a risk and benefit assessment of the data from the ongoing trial that was conducted by the independent Data Monitoring Committee (DMC) followed by a select group of unblinded individuals at Keros.
The decision to halt the dosing in 3.0 mg/kg and 4.5 mg/kg treatment arms and continue dosing in the 1.5 mg/kg treatment arm was made in consultation with the independent DMC for the trial.
The company intends to continue ongoing safety and efficacy data collection for all treatment arms in the trial.
The company continues to expect to present topline data from all treatment arms in this trial in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40684511/keros-therapeutics-announces-update-on-enrollment-in-the-phase-2-tropos-trial" rel="noreferrer noopener">second quarter of 2025</a>.
Price Action: KROS stock is down 74.1% at $17.80&nbsp;during the premarket session at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42457904/tat-technologies-secures-17-million-mro-deal-with-major-cargo-carrier-to-repair-apus-for-boeing-757-and-767-aircraft" target="_blank" rel="noreferrer noopener">TAT Technologies Secures $17 Million MRO Deal With Major Cargo Carrier: Details</a></li>
</ul>

Health Care

Movers

KROS

Keros Therapeutics Loses 75% Value In A Single Session - Here's Why

JMP Securities analyst Silvan Tuerkcan reiterates Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Market Outperform and maintains $21 price target.

Reiteration

RLAY

JMP Securities Reiterates Market Outperform on Relay Therapeutics, Maintains $21 Price Target

LeddarTech Holdings (LDTC) has released an update. LeddarTech Holdings has received a US$3.0 million bridge loan, marking the second tranche of a U...

LeddarTech Secures $3 Million in Bridge Financing

LeddarTech (LDTC) announced that the International Organization for Standardization and the International Electrotechnical Commission have awarded ...

LeddarTech awarded ISO/IEC 270001 certification

LeddarTech (LDTC) provides an update with respect to the previously disclosed bridge financing offer entered into with the initial bridge lenders a...

LeddarTech provides financing update

LeddarTech Holdings (LDTC) has released an update. LeddarTech Holdings has announced that, despite not meeting the initial deadline for securing eq...

LeddarTech Continues Financing Efforts Amidst Challenges

LeddarTech Holdings (LDTC) announced that LeddarTech and Texas Instruments (TXN) have entered into a strategic collaboration agreement and a softwa...

LeddarTech enters into amendments to credit facility, bridge financing

LeddarTech (LDTC) announced that LeddarTech and Texas Instruments (TXN) have entered into a strategic collaboration agreement and a software licens...

LeddarTech announces collboration agreement with Texas Instruments

LeddarTech Holdings (LDTC) has released an update. LeddarTech Holdings Inc. has announced amendments to its bridge financing agreement, aimed at ex...

LeddarTech Secures Amended Financing for Growth

TD Cowen analyst Joshua Buchalter maintained a Hold rating on LeddarTech Holdings (LDTC – Research Report) today. The company's shares closed yeste...

LeddarTech Holdings (LDTC) Receives a Hold from TD Cowen

Roth MKM analyst Sujeeva De Silva maintained a Buy rating on LeddarTech Holdings (LDTC – Research Report) today and set a price target of $3.00. Th...

LeddarTech Holdings (LDTC) Receives a Buy from Roth MKM

Roth MKM raised the firm's price target on LeddarTech (LDTC) to $3 from $1 and keeps a Buy rating on the shares. The firm cites the company's annou...

LeddarTech price target raised to $3 from $1 at Roth MKM

LDTC

Financing

Press Releases

LeddarTech Announces Receipt of US$3.0 Million Following Disbursement of the Second Tranche of the Previously Announced Bridge Financing

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

LeddarTech Fortifies Its Cybersecurity Framework with ISO/IEC 27001 Certification

LeddarTech Provides Financing Update

LeddarTech Announces Presence at CES 2025, Las Vegas: Demonstrating Their Latest AI-Driven Automotive Software in Collaboration with Arm and Texas Instruments

LeddarTech Announces Collaboration with Texas Instruments for Advanced Driver Assistance Systems and Autonomous Driving Solutions

LeddarTech Enters Into Amendments to Credit Facility and Bridge Financing Offer

Stocks to Watch in December 2025: LDTC, CPIX, PNPN.V, ZEO, and More Inside

AEMD

ASPI

BIXT

BNRG

BTVRF

BVAXF

CLLXF

CMRX

CPIX

CRDF

CSE:BIOV

CSE:ELEM

CSE:PLUG

CYIO

ELMGF

EUDA

GIFT

GOSS

ICON

IMRN

KGFMF

MNMRF

NCSM

NRXBF

NRXP

PGEZF

PLGGF

PNPNF

PRSO

RGBP

SEVCF

SIGY

STRRF

STXPF

TSX:VOXR

TSXV:BTV

TSXV:CNX

TSXV:KFR

TSXV:MNRG

TSXV:NRX

TSXV:PGE

TSXV:PNPN

TSXV:STU

TSXV:VRR

TSXV:XBOT

VANI

VIOT

VOXR

VRRCF

XBOTF

ReAlpha Tech

XIAO-I Corporation - American Depositary Shares

XIAO-I

Argo Blockchain plc - American Depositary Shares

Argo Blockchain

Aware

BIT Mining

BTCS

BTC Digital

Gorilla Technology Group Inc. - Ordinary shares

Gorilla Tech Gr

MicroCloud Hologram Inc. - Ordinary Shares

MicroCloud Hologram

Heartcore Enterprises, Inc. - Common Stock

HeartCore Enterprises

Intellicheck

Inuvo

Issuer Direct

Aurora Mobile Limited - American Depositary Shares

Aurora Mobile

LivePerson

MMTEC

NETSOL Technologies

OneConnect Financial Technology Co., Ltd. American Depositary Shares, each representing thirty ordinary shares

Comments

LeddarTech Holdings

LeddarTech Holdings (LDTC) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル